Product Images Serevent Diskus

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 14 images provide visual information about the product associated with Serevent Diskus NDC 68258-8961 by Dispensing Solutions, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

salmeterol xinafoate chemical structure - 42aa9a5a c1f5 41ae ba72 e9a46db63786 01

salmeterol xinafoate chemical structure - 42aa9a5a c1f5 41ae ba72 e9a46db63786 01

Figure 1. Serial 12-Hour FEV1 From Two 12-Week Clinical Trials in Patients With Asthma First Treatment Day - 42aa9a5a c1f5 41ae ba72 e9a46db63786 02

Figure 1. Serial 12-Hour FEV1 From Two 12-Week Clinical Trials in Patients With Asthma First Treatment Day - 42aa9a5a c1f5 41ae ba72 e9a46db63786 02

Last Treatment Day (Week 12) - 42aa9a5a c1f5 41ae ba72 e9a46db63786 03

Last Treatment Day (Week 12) - 42aa9a5a c1f5 41ae ba72 e9a46db63786 03

Figure 2. Cumulative Incidence of Asthma-Related Deaths in the 28-Week Salmeterol Multi-center Asthma Research Trial (SMART), by Duration of Treatment - 42aa9a5a c1f5 41ae ba72 e9a46db63786 04

Figure 2. Cumulative Incidence of Asthma-Related Deaths in the 28-Week Salmeterol Multi-center Asthma Research Trial (SMART), by Duration of Treatment - 42aa9a5a c1f5 41ae ba72 e9a46db63786 04

Figure 3. Mean Percent Change From Baseline in Postdose FEV1 Integrated Data From 2 Trials of Patients With Chronic Bronchitis and Airflow Limitation - 42aa9a5a c1f5 41ae ba72 e9a46db63786 05

Figure 3. Mean Percent Change From Baseline in Postdose FEV1 Integrated Data From 2 Trials of Patients With Chronic Bronchitis and Airflow Limitation - 42aa9a5a c1f5 41ae ba72 e9a46db63786 05

This text appears to be a medication dosage instruction for SEREVENTDISKUS. It suggests taking 50mg of the medication twice a day. There is also some mention of a baseline FEV and placebo, possibly indicating the medication's efficacy compared to a control group. The word "Endpoint" is also present, but it is unclear what it refers to without further context.*

Figure 4. Serial 12-Hour FEV1 on the First Day and at Week 12 of Treatment - 42aa9a5a c1f5 41ae ba72 e9a46db63786 06

Figure 4. Serial 12-Hour FEV1 on the First Day and at Week 12 of Treatment - 42aa9a5a c1f5 41ae ba72 e9a46db63786 06

PIL parts figure - 42aa9a5a c1f5 41ae ba72 e9a46db63786 07

PIL parts figure - 42aa9a5a c1f5 41ae ba72 e9a46db63786 07

PIL Figure 1 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 08

PIL Figure 1 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 08

PIL Figure 2 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 09

PIL Figure 2 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 09

PIL Figure 3 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 10

PIL Figure 3 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 10

PIL Figure 4 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 11

PIL Figure 4 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 11

PIL Figure 5 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 12

PIL Figure 5 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 12

PIL Figure 6 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 13

PIL Figure 6 - 42aa9a5a c1f5 41ae ba72 e9a46db63786 13

NDC 68258-8961-06 - NDC 68258 8961 06 GLAXOSMITHKLINE

NDC 68258-8961-06 - NDC 68258 8961 06        GLAXOSMITHKLINE

This document contains information on a medication called SEREVENT DISKUS, manufactured by GlaxoSmithKline. It is an inhalation powder and comes in a package with teal, white, yellow, black, and orange colors, and the product ID is NDC 0173-0521-00. The document provides details on the product's dosage, manufacturer lot, and dispensing information. It is recommended to read the medication guide provided with the package, and the powder should be discarded six weeks after removal from the overwrap. This document also warns to keep the medication out of children's reach and store it at 68°- 77° F.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.